Your browser doesn't support javascript.
loading
Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection.
Holtkamp, Lodewijka H J; Lo, Serigne N; Thompson, John F; Spillane, Andrew J; Stretch, Jonathan R; Saw, Robyn P M; Shannon, Kerwin F; Nieweg, Omgo E; Hong, Angela M.
Afiliación
  • Holtkamp LHJ; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
  • Lo SN; Department of Surgical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
  • Thompson JF; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
  • Spillane AJ; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Stretch JR; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
  • Saw RPM; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Shannon KF; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Nieweg OE; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
  • Hong AM; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
J Surg Oncol ; 128(1): 97-104, 2023 Jul.
Article en En | MEDLINE | ID: mdl-36971691
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Adjuvant radiotherapy (RT) can be given to melanoma patients following salvage surgery for node field recurrence after a previous regional node dissection, but the value of this treatment strategy is poorly documented. This study evaluated long-term node field control and survival of patients treated in this way in an era before effective adjuvant systemic therapy became available.

METHODS:

Data for 76 patients treated between 1990 and 2011 were extracted from an institutional database. Baseline patient characteristics, treatment details and oncological outcomes were analysed.

RESULTS:

Adjuvant RT with conventional fractionation (median dose 48 Gy in 20 fractions) was given to 43 patients (57%) and hypofractionated RT (median dose 33 Gy in 6 fractions) to 33 patients (43%). The 5-year node field control rate was 70%, 5-year recurrence-free survival 17%, 5-year melanoma-specific survival 26% and 5-year overall survival 25%.

CONCLUSIONS:

Salvage surgery with adjuvant RT achieved node field control in 70% of melanoma patients with node field recurrence following a prior node dissection. However, disease progression at distant sites was common and survival outcomes were poor. Prospective data will be required to assess outcomes for contemporary combinations of surgery, adjuvant RT and systemic therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: J Surg Oncol Año: 2023 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: J Surg Oncol Año: 2023 Tipo del documento: Article País de afiliación: Australia